NDLI: Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer

Content Provider	Springer Nature : BioMed Central
Author	Sato, Hiromi Narita, Shintaro Tsuchiya, Norihiko Koizumi, Atsushi Nara, Taketoshi Kanda, Sohei Numakura, Kazuyuki Tsuruta, Hiroshi Maeno, Atsushi Saito, Mitsuru Inoue, Takamitsu Satoh, Shigeru Nomura, Kyoko Habuchi, Tomonori
Abstract	Background Less evidence is known about the role of early changes in serum biomarker after androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Here we evaluated the impact of pre-treatment prognostic factors and early changes in serum biomarkers on prostate specific antigen (PSA) progression-free and overall survival rates in mHSPC. Methods We retrospectively reviewed the medical records of 60 mHSPC patients (median age 72 years) treated with ADT whose laboratory data at baseline and following 12 weeks were available. Results Forty-four patients (73%) had PSA progression and 27 patients (45.0%) died during a median follow-up of 34 months. The multivariable Cox hazard model demonstrated that a log-transformed baseline PSA level (p = 0.003) and an extent of bone disease (EOD) score of ≥3 (p = 0.004) were statistically associated with an increased risk for PSA progression whereas one unit increase in a log-transformed PSA change (baseline-12 weeks) was associated with a decreased risk for PSA progression (p = 0.004). For overall survival, a high level of alkaline phosphatase (ALP) at 12 weeks was associated with increased risk (p = 0.030) whereas a one-unit increase in the log-transformed PSA change was associated with decreased risk (p = 0.001). Conclusions An increased level of PSA at baseline, or an EOD score of ≥3 may be a good predictor of PSA progression, and a high level of ALP at 12 weeks may be a risk predictor of death. A larger decline in PSA at 12 weeks from the baseline was associated with both PSA progression-free and overall survival time. Early changes in serum biomarkers may be useful in predicting poor outcomes in patients with mHSPC who are initially treated with ADT.
Related Links	https://bmcurol.biomedcentral.com/counter/pdf/10.1186/s12894-018-0353-4.pdf
Ending Page	8
Page Count	8
Starting Page	1
File Format	HTM / HTML
ISSN	14712490
DOI	10.1186/s12894-018-0353-4
Journal	BMC Urology
Issue Number	1
Volume Number	18
Language	English
Publisher	BioMed Central
Publisher Date	2018-05-08
Access Restriction	Open
Subject Keyword	Urology Internal Medicine Metastatic Hormone-sensitive Prostate Cancer Serum Biomarkers Androgen Deprivation Therapy Early Changes Prostate-specific Antigen (PSA)
Content Type	Text
Resource Type	Article
Subject	Urology Reproductive Medicine
Journal Impact Factor	1.7/2023
5-Year Journal Impact Factor	2/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy

Predictors of survival outcomes in native sub Saharan black men newly diagnosed with metastatic prostate cancer

Association of Time to PSA Nadir and Logarithm of PSA Velocity After Progression in Metastatic Prostate Cancer with Prior Primary Androgen Deprivation Therapy

A simple computer program for calculating PSA recurrence in prostate cancer patients

Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT

Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer

Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer

Prostate specific antigen ( PSA ) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy :

Prostate cancer: metastatic

Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer

Similar Documents

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy

Predictors of survival outcomes in native sub Saharan black men newly diagnosed with metastatic prostate cancer

Association of Time to PSA Nadir and Logarithm of PSA Velocity After Progression in Metastatic Prostate Cancer with Prior Primary Androgen Deprivation Therapy

A simple computer program for calculating PSA recurrence in prostate cancer patients

Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT

Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer

Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer

Prostate specific antigen ( PSA ) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy :

Prostate cancer: metastatic

Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer